Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients

Inclusion Criteria:

Age >/= 18 years
Confirmed diagnosis of unresectable epithelial ovarian, fallopian tube or primary peritoneal cancer.
Platinum-resistant disease (PFI: 1-6 months after last platinum-containing chemotherapy).
Evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria
No more than three prior systemic chemotherapy regimens
Eastern Cooperative Oncology Group (ECOG) performance status (PS) (ECOG PS) ≤ 2
Adequate hematological, renal, metabolic and hepatic function

Exclusion Criteria:

Concomitant diseases/conditions: cardiac disease, immunodeficiency, chronic active hepatitis or cirrhosis, uncontrolled infection, bowel obstruction, any other major illness
Prior treatment with PM01183, trabectedin, or with both PLD and topotecan.
Requirement of permanent or frequent (i.e., once per week) external drainages within two weeks prior to randomization